Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS.

ABSTRACT: The discovery of NO as both an endogenous signalling molecule and as a mediator of the cardiovascular effects of organic nitrates was acknowledged in 1998 by the Nobel Prize in Physiology/Medicine. The characterization of its downstream signalling, mediated through stimulation of soluble GC (sGC) and cGMP generation, initiated significant translational interest, but until recently this was almost exclusively embodied by the use of PDE5 inhibitors in erectile dysfunction. Since then, research progress in two areas has contributed to an impressive expansion of the therapeutic targeting of the NO-sGC-cGMP axis: first, an increased understanding of the molecular events operating within this complex pathway and second, a better insight into its dys-regulation and uncoupling in human disease. Al

SUBMITTER: Papapetropoulos A 

PROVIDER: S-EPMC4369253 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature